Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
2.65
Change:
- 0.04
Volume:
2,151,200
4:00 PM ET on Apr 17, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

Apr 11, 2014
Immune Responses Enhanced and Sustained When PROVENGE® (sipuleucel-T) is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer

Mar 3, 2014
Dendreon Announces Plans to Make PROVENGE® Commercially Available in Europe

Mar 3, 2014
Dendreon Announces Fourth Quarter and 2013 Year End Results



View all »Webcasts

Mar 4, 2014 at 11:20 AM ET
Cowen and Company 34th Annual Health Care Conference

Mar 3, 2014 at 9:00 AM ET
Q4 and Year End 2013 Earnings Conference Call



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com